Home Cart 0 Sign in  

[ CAS No. 722544-51-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 722544-51-6
Chemical Structure| 722544-51-6
Structure of 722544-51-6 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 722544-51-6 ]

Related Doc. of [ 722544-51-6 ]

Alternatived Products of [ 722544-51-6 ]

Product Details of [ 722544-51-6 ]

CAS No. :722544-51-6 MDL No. :MFCD17392583
Formula : C26H30FN7O3 Boiling Point : -
Linear Structure Formula :- InChI Key :QYZOGCMHVIGURT-UHFFFAOYSA-N
M.W : 507.56 Pubchem ID :16007391
Synonyms :
AZD1152-HQPA;AZD2811;Defosbarasertib;Barasertib;INH-34

Calculated chemistry of [ 722544-51-6 ]

Physicochemical Properties

Num. heavy atoms : 37
Num. arom. heavy atoms : 21
Fraction Csp3 : 0.31
Num. rotatable bonds : 14
Num. H-bond acceptors : 8.0
Num. H-bond donors : 4.0
Molar Refractivity : 139.38
TPSA : 128.29 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -7.27 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.7
Log Po/w (XLOGP3) : 3.0
Log Po/w (WLOGP) : 3.73
Log Po/w (MLOGP) : 1.93
Log Po/w (SILICOS-IT) : 3.68
Consensus Log Po/w : 3.21

Druglikeness

Lipinski : 1.0
Ghose : None
Veber : 1.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.37
Solubility : 0.0215 mg/ml ; 0.0000424 mol/l
Class : Moderately soluble
Log S (Ali) : -5.36
Solubility : 0.00222 mg/ml ; 0.00000438 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -9.07
Solubility : 0.000000435 mg/ml ; 0.0000000009 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.87

Safety of [ 722544-51-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 722544-51-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 722544-51-6 ]
  • Downstream synthetic route of [ 722544-51-6 ]

[ 722544-51-6 ] Synthesis Path-Upstream   1~8

  • 1
  • [ 722544-46-9 ]
  • [ 110-73-6 ]
  • [ 722544-51-6 ]
YieldReaction ConditionsOperation in experiment
85% at 90℃; for 12 - 16 h; 2-(3-[7-(3-Chloropropoxy)quinazolin-4-yl]amino}-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide and 2-(ethylamino)ethanol (ideally 12 molar equivalents) were added to N,N-dimethylacetamide under an inert atmosphere (such as provided by nitrogen) and the mixture heated to 90° C. with stirring.
After a period of 12-16 hours (ideally 12 hours) the reaction is cooled back to about 85° C. and water added in a controlled manner to maintain the temperature between 80-85° C.
The batch is adjusted to 80° C. and seeded with crystals of the preferred form of the product (ideally an amount of about 1percent of the expected yield).
The mixture was cooled to 20° C. in a carefully controlled manner over a period of about 20 hours so as to crystallise the product in the required form and of a size sufficient to afford a good filtration rate.
The product is then filtered and washed with a mixture of water/N,N-dimethylacetamide and acetonitrile and suitably deliquored to afford a hydrated form of the product.
Following this, the cake is slurried in situ for a period (ideally 2 hours) with warm acetonitrile (ideally at a temperature of 40° C.) then filtered, washed with more acetonitrile and then dried (in vacuo or under a stream of nitrogen) to afford the almost anhydrous 2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1H-pyrazol-5-yl}-N-(3-fluorophenyl)acetamide as an off-white solid in a yield of 85-90percent.
1H-NMR (DMSO d6): 10.55 (s, 1H), 9.45 (br s, 1H), 8.98 (s, 1H), 8.8 (d, 1H), 7.63 (pr of m, 1H), 7.47 (pr of d, 1H), 7.37 (m, 2H), 7.32 (d, 1H), 6.9 (m, 1H), 6.77 (s, 1H), 4.32 (t, 2H), 3.83 (br s, 2H), 3.76 (t, 2H), 3.35 (m, 2H), 3.25 (m, 4H), 2.25 (m, 2H), 1.25 (t, 3H):
MS (+ve ESI): 508.4 (M+H)+.
85% at 80 - 90℃; for 12 - 16 h; 2-(3-[7-(3-Chloropropoxy)quinazolin-4-yl]amino}-lH-pyrazol-5-yl)-N-(3- fluorophenyl)acetamide and 2-(ethylamino)ethanol (12 molar equivalents) were added to N,N-dimethylacetamide under an inert atmosphere (such as provided by nitrogen) and the mixture heated to 9O0C with stirring. After 12 hours, water was added in a controlled manner and the batch seeded with product whilst hot. The mixture was cooled to 2O0C in a carefully controlled manner to crystallise the product in the required form. The product was then filtered and washed with a mixture of water/ N,N-dimethylacetamide and acetonitrile. Following this, the cake was slurried for a period with warm acetonitrile (4O0C), filtered, washed with more acetonitrile and then dried (in vacuo or under a stream of nitrogen) to afford the anhydrous 2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}- quinazolin-4-yl)amino]-lH-pyrazol-5-yl}- N-(3-fluorophenyl)acetamide as an off-white solid in a yield of -90percent . 1H-NMR (DMSO d6): 10.55 (s, IH), 9.45 (br s, IH), 8.98 (s, IH), 8.8 (d, IH), 7.63 (pr of m, IH), 7.47 (pr of d, IH), 7.37 (m, 2H), 7.32 (d, IH), 6.9 (m, IH), 6.77 (s, IH), 4.32 (t, 2H), 3.83 (br s, 2H), 3.76 (t, 2H), 3.35 (m, 2H), 3.25 (m, 4H), 2.25 (m, 2H), 1.25 (t, 3H): MS (+ve ESI) : 508.4 (M+H)+.; 2-(3-[7-(3-Chloropropoxy)quinazolin-4-yl]amino}-lH-pyrazol-5-yl)-N-(3- fluorophenyl)acetamide and 2-(ethylamino)ethanol (ideally 12 molar equivalents) were added to N.N-dimethylacetamide under an inert atmosphere (such as provided by nitrogen) and the mixture heated to 90°C with stirring. After a period of 12 - 16 hours (ideally 12 hours) the reaction is cooled back to about 850C and water added in a controlled manner to maintain the temperature between 80 - 85°C. The batch is adjusted to 8O0C and seeded with crystals of the preferred form of the product (ideally an amount of about 1percent of the expected yield). The mixture was cooled to 200C in a carefully controlled manner over a period of about 20 hours so as to crystallise the product in the required form and of a size sufficient to afford a good filtration rate. The product is then filtered and washed with a mixture of water / N,N-dimethylacetamide and acetonitrile and suitably deliquored to afford a hydrated form of the product. Following this, the cake is slurried in situ for a period (ideally 2 hours) with warm acetonitrile (ideally at a temperature of 4O0C) then filtered, washed with more acetonitrile and then dried (in vacuo or under a stream of nitrogen) to afford the almost anhydrous 2-{3-[(7-{3-[ethyl(2- hydroxyethyl)amino]propoxy} -quinazolin-4-yl)amino]- lH-pyrazol-5-yl} - N-(3- fluorophenyl)acetamide as an off-white solid in a yield of 85 - 90percent. 1H-NMR (DMSO d6): 10.55 (s, IH), 9.45 (br s, IH), 8.98 (s, IH), 8.8 (d, IH), 7.63 (pr of m, IH), 7.47 (pr of d, IH), 7.37 (m, 2H), 7.32 (d, IH), 6.9 (m, IH), 6.77 (s, IH), 4.32 (t, 2H), 3.83 (br s, 2H), 3.76 (t, 2H), 3.35 (m, 2H), 3.25 (m, 4H), 2.25 (m, 2H), 1.25 (t, 3H): MS (+ve ESI) : 508.4 (M+H)+.
85% at 20 - 90℃; for 32 - 36 h; 2-(3-[7-(3-Chloropropoxy)quinazolin-4-yl]amino}-lH-pyrazol-5-yl)-N-(3- fluorophenyl)acetamide and 2-(ethylamino)ethanol (ideally 12 molar equivalents) were added to N,N-dimethylacetamide under an inert atmosphere (such as provided by nitrogen) and the mixture heated to 900C with stirring. After a period of 12 - 16 hours (ideally 12 hours) the reaction is cooled back to about 850C and water added in a controlled manner to maintain the temperature between 80 - 85°C. The batch is adjusted to 8O0C and seeded with crystals of the preferred form of the product (ideally an amount of about 1percent of the expected yield). The mixture was cooled to 2O0C in a carefully controlled manner over a period of about 20 hours so as to crystallise the product in the required form and of a size sufficient to afford a good filtration rate. The product is then filtered and washed with a mixture of water / N,N-dimethylacetamide and acetonitrile and suitably deliquored to afford a hydrated form of the product. Following this, the cake is slurried in situ for a period (ideally 2 hours) with warm acetonitrile (ideally at a temperature of 4O0C) then filtered, washed with more acetonitrile and then dried (in vacuo or under a stream of nitrogen) to afford the almost anhydrous 2-{3-[(7-{3-[ethyl(2- <n="27"/>hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-lH-pyrazol-5-yl}- N-(3- fluorophenyl)acetamide as an off-white solid in a yield of 85 - 90percent . 1H-NMR (DMSO d6): 10.55 (s, IH)5 9.45 (br s, IH), 8.98 (s, IH), 8.8 (d, IH), 7.63 (pr of m, IH), 7.47 (pr of d, IH), 7.37 (m, 2H), 7.32 (d, IH), 6.9 (m, IH), 6.77 (s, IH), 4.32 (t, 2H), 3.83 (br s, 2H), 3.76 (t, 2H), 3.35 (m, 2H), 3.25 (m, 4H), 2.25 (m, 2H), 1.25 (t, 3H): MS (+ve ESI) : 508.4 (M+H)+.
Reference: [1] Patent: US2007/270384, 2007, A1, . Location in patent: Page/Page column 9; 11
[2] Patent: WO2007/132227, 2007, A1, . Location in patent: Page/Page column 26; 30
[3] Patent: WO2007/132215, 2007, A1, . Location in patent: Page/Page column 25-26
[4] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2213 - 2224
[5] Patent: WO2007/132215, 2007, A1, . Location in patent: Page/Page column 19
  • 2
  • [ 557770-89-5 ]
  • [ 722544-51-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2213 - 2224
[2] Patent: WO2007/132227, 2007, A1,
[3] Patent: WO2007/132215, 2007, A1,
  • 3
  • [ 557770-90-8 ]
  • [ 722544-51-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2213 - 2224
[2] Patent: WO2007/132227, 2007, A1,
[3] Patent: WO2007/132215, 2007, A1,
  • 4
  • [ 16499-57-3 ]
  • [ 722544-51-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2213 - 2224
[2] Patent: WO2007/132227, 2007, A1,
[3] Patent: WO2007/132215, 2007, A1,
  • 5
  • [ 557770-91-9 ]
  • [ 722544-51-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2213 - 2224
[2] Patent: WO2007/132215, 2007, A1,
  • 6
  • [ 446-32-2 ]
  • [ 722544-51-6 ]
Reference: [1] Patent: WO2007/132227, 2007, A1,
[2] Patent: WO2007/132215, 2007, A1,
  • 7
  • [ 174891-10-2 ]
  • [ 722544-51-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2007, vol. 50, # 9, p. 2213 - 2224
  • 8
  • [ 372-19-0 ]
  • [ 722544-51-6 ]
Reference: [1] Patent: WO2007/132215, 2007, A1,
Same Skeleton Products
Historical Records